Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2026-06-23 16:01:08 ET · period of report 2026-06-22 · accession 0001213900-26-071075 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-23 16:01 | 2026-06-22 | MLTX | Bodenstedt Matthias | CFO | S - Sale | $22.04 | -39.1K | 1.12M | -3% | -$862.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2026-06-22 | S | D | 39,120 | $22.04 | 1,115,435 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.87 to $23.2049. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |